Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever

Detalhes bibliográficos
Autor(a) principal: Oliveira, Acary Souza Bulle [UNIFESP]
Data de Publicação: 2009
Outros Autores: Pereira, Roberto Dias Batista [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0004-282X2009000400040
http://repositorio.unifesp.br/handle/11600/5240
Resumo: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the motor nervous system. It causes progressive and cumulative physical disabilities in patients, and leads to eventual death due to respiratory muscle failure. The disease is diverse in its presentation, course, and progression. We do not yet fully understand the cause or causes of the disease, nor the mechanisms for its progression; thus, we lack effective means for treating this disease. Currently, we rely on a multidisciplinary approach to symptomatically manage and care for patients who have ALS. Although amyotrophic lateral sclerosis and its variants are readily recognized by neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are common. Prompt diagnosis, sensitive communication of the diagnosis, the involvement of the patient and their family, and a positive care plan are prerequisites for good clinical management. A multidisciplinary, palliative approach can prolong survival and maintain quality of life. Treatment with Riluzole improves survival but has a marginal effect on the rate of functional deterioration, whereas non-invasive ventilation prolongs survival and improves or maintains quality of life. In this Review, we discuss the diagnosis, management, and how to cope with impaired function and end of life on the basis of our experience, the opinions of experts, existing guidelines, and clinical trials. Multiple problems require a multidisciplinary approach including aggressive symptomatic management, rehabilitation to maintain motor function, nutritional support (enteric feeding, gastrostomy), respiratory support (non invasive home ventilation, invasive ventilation, tracheotomy), augmentative communication devices, palliative care, psychological support for both patients and families (because family members so often play a central role in management and care), communication between the care team, the patient and his or her family, and recognition of the clinical and social effects of cognitive impairment. Social, bioethical, and financial issues as well as advance directives should be addressed. A plethora of evidence-based guidelines should be compiled into an internationally agreed guideline of best practice. The multidisciplinary team has changed the history of disease, with still no curative therapy available.
id UFSP_3893580cc9a87d87d5870c0fc5171c1e
oai_identifier_str oai:repositorio.unifesp.br/:11600/5240
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For everEsclerose lateral amiotrófica (ELA): três letras que mudam a vida de uma pessoa. Para sempreamyotrophic lateral sclerosisdiagnosistreatmentesclerose lateral amiotróficadiagnósticotratamentoAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the motor nervous system. It causes progressive and cumulative physical disabilities in patients, and leads to eventual death due to respiratory muscle failure. The disease is diverse in its presentation, course, and progression. We do not yet fully understand the cause or causes of the disease, nor the mechanisms for its progression; thus, we lack effective means for treating this disease. Currently, we rely on a multidisciplinary approach to symptomatically manage and care for patients who have ALS. Although amyotrophic lateral sclerosis and its variants are readily recognized by neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are common. Prompt diagnosis, sensitive communication of the diagnosis, the involvement of the patient and their family, and a positive care plan are prerequisites for good clinical management. A multidisciplinary, palliative approach can prolong survival and maintain quality of life. Treatment with Riluzole improves survival but has a marginal effect on the rate of functional deterioration, whereas non-invasive ventilation prolongs survival and improves or maintains quality of life. In this Review, we discuss the diagnosis, management, and how to cope with impaired function and end of life on the basis of our experience, the opinions of experts, existing guidelines, and clinical trials. Multiple problems require a multidisciplinary approach including aggressive symptomatic management, rehabilitation to maintain motor function, nutritional support (enteric feeding, gastrostomy), respiratory support (non invasive home ventilation, invasive ventilation, tracheotomy), augmentative communication devices, palliative care, psychological support for both patients and families (because family members so often play a central role in management and care), communication between the care team, the patient and his or her family, and recognition of the clinical and social effects of cognitive impairment. Social, bioethical, and financial issues as well as advance directives should be addressed. A plethora of evidence-based guidelines should be compiled into an internationally agreed guideline of best practice. The multidisciplinary team has changed the history of disease, with still no curative therapy available.A esclerose lateral amiotrófica (ELA) é doença neurodegenerativa comprometendo o sistema nervoso motor. Ela causa comprometimento físico, progressivo e acumulativo, com óbito freqüentemente decorrente de falência respiratória. A enfermidade apresenta características diversas nas formas de apresentação, curso e progressão. Não entendemos ainda a causa ou causas dessa enfermidade, nem os mecanismos que regem a sua progressão; assim, tratamentos efetivos não são, até o momento, conhecidos. Atualmente, recomenda-se que os pacientes com ELA sejam tratados com equipe multidisciplinar. Embora ELA e suas variantes sejam reconhecidas por neurologistas, cerca de 10% dos pacientes são mal diagnosticados, e a demora para a confirmação diagnóstica não é incomum. Diagnóstico precoce, informação do diagnóstico com honestidade e sensibilidade, envolvimento do paciente e sua família, e um plano de atenção terapêutica positivo são pré-requisitos essenciais para um melhor resultado clínico e fim terapêutico. Tratamento multidisciplinar e cuidados paliativos podem prolongar a sobrevida e manter melhores aspectos de qualidade de vida. Tratamento com Riluzol aumenta a sobrevida, mas sem alteração na deterioração funcional, enquanto que ventilação não-invasiva prolonga a sobrevida e aumenta ou mantém qualidade de vida. Nesta revisão, nós discutimos o diagnóstico, envolvimento e formas de lidar com dificuldades de funcionamento e de fim de vida, baseando-se na nossa experiência, nos pareceres de peritos, em guias de medicina baseada em evidências científicas, e nos ensaios clínicos. Problemas múltiplos exigem uma abordagem multidisciplinar, incluindo-se tratamento sintomático agressivo, reabilitação para manter a função motora, apoio nutricional (alimentação entérica, gastrostomia), suporte respiratório (ventilação domiciliar não-invasiva, ventilação invasiva, traqueostomia), dispositivo para comunicação aumentativa, cuidados paliativos, apoio psicológico para ambos, pacientes e familiares (uma vez que os familiares, muitas vezes, desempenham um papel central na gestão e no atendimento), a comunicação entre equipe multidisciplinar, o paciente e sua família, bem como o reconhecimento da clínica e os efeitos sociais do declínio cognitivo. Questões sociais, financeiras e de bioética também devem ser consideradas. A multiplicidade de orientações com base em guias de consensos de melhor prática clínica devem ser fornecidas para os pacientes com ELA. As orientações multidisciplinares têm mudado a história desta doença, ainda com nenhuma terapia curativa disponível.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de NeurologiaUNIFESP, EPM, Depto. de NeurologiaSciELOAcademia Brasileira de Neurologia - ABNEUROUniversidade Federal de São Paulo (UNIFESP)Oliveira, Acary Souza Bulle [UNIFESP]Pereira, Roberto Dias Batista [UNIFESP]2015-06-14T13:41:09Z2015-06-14T13:41:09Z2009-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion750-782application/pdfhttp://dx.doi.org/10.1590/S0004-282X2009000400040Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 67, n. 3a, p. 750-782, 2009.10.1590/S0004-282X2009000400040S0004-282X2009000400040.pdf0004-282XS0004-282X2009000400040http://repositorio.unifesp.br/handle/11600/5240WOS:000269463500040engArquivos de Neuro-Psiquiatriainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-28T18:22:12Zoai:repositorio.unifesp.br/:11600/5240Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-28T18:22:12Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
Esclerose lateral amiotrófica (ELA): três letras que mudam a vida de uma pessoa. Para sempre
title Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
spellingShingle Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
Oliveira, Acary Souza Bulle [UNIFESP]
amyotrophic lateral sclerosis
diagnosis
treatment
esclerose lateral amiotrófica
diagnóstico
tratamento
title_short Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
title_full Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
title_fullStr Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
title_full_unstemmed Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
title_sort Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever
author Oliveira, Acary Souza Bulle [UNIFESP]
author_facet Oliveira, Acary Souza Bulle [UNIFESP]
Pereira, Roberto Dias Batista [UNIFESP]
author_role author
author2 Pereira, Roberto Dias Batista [UNIFESP]
author2_role author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Oliveira, Acary Souza Bulle [UNIFESP]
Pereira, Roberto Dias Batista [UNIFESP]
dc.subject.por.fl_str_mv amyotrophic lateral sclerosis
diagnosis
treatment
esclerose lateral amiotrófica
diagnóstico
tratamento
topic amyotrophic lateral sclerosis
diagnosis
treatment
esclerose lateral amiotrófica
diagnóstico
tratamento
description Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the motor nervous system. It causes progressive and cumulative physical disabilities in patients, and leads to eventual death due to respiratory muscle failure. The disease is diverse in its presentation, course, and progression. We do not yet fully understand the cause or causes of the disease, nor the mechanisms for its progression; thus, we lack effective means for treating this disease. Currently, we rely on a multidisciplinary approach to symptomatically manage and care for patients who have ALS. Although amyotrophic lateral sclerosis and its variants are readily recognized by neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are common. Prompt diagnosis, sensitive communication of the diagnosis, the involvement of the patient and their family, and a positive care plan are prerequisites for good clinical management. A multidisciplinary, palliative approach can prolong survival and maintain quality of life. Treatment with Riluzole improves survival but has a marginal effect on the rate of functional deterioration, whereas non-invasive ventilation prolongs survival and improves or maintains quality of life. In this Review, we discuss the diagnosis, management, and how to cope with impaired function and end of life on the basis of our experience, the opinions of experts, existing guidelines, and clinical trials. Multiple problems require a multidisciplinary approach including aggressive symptomatic management, rehabilitation to maintain motor function, nutritional support (enteric feeding, gastrostomy), respiratory support (non invasive home ventilation, invasive ventilation, tracheotomy), augmentative communication devices, palliative care, psychological support for both patients and families (because family members so often play a central role in management and care), communication between the care team, the patient and his or her family, and recognition of the clinical and social effects of cognitive impairment. Social, bioethical, and financial issues as well as advance directives should be addressed. A plethora of evidence-based guidelines should be compiled into an internationally agreed guideline of best practice. The multidisciplinary team has changed the history of disease, with still no curative therapy available.
publishDate 2009
dc.date.none.fl_str_mv 2009-09-01
2015-06-14T13:41:09Z
2015-06-14T13:41:09Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0004-282X2009000400040
Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 67, n. 3a, p. 750-782, 2009.
10.1590/S0004-282X2009000400040
S0004-282X2009000400040.pdf
0004-282X
S0004-282X2009000400040
http://repositorio.unifesp.br/handle/11600/5240
WOS:000269463500040
url http://dx.doi.org/10.1590/S0004-282X2009000400040
http://repositorio.unifesp.br/handle/11600/5240
identifier_str_mv Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 67, n. 3a, p. 750-782, 2009.
10.1590/S0004-282X2009000400040
S0004-282X2009000400040.pdf
0004-282X
S0004-282X2009000400040
WOS:000269463500040
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Arquivos de Neuro-Psiquiatria
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 750-782
application/pdf
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268313429082112